Champions Oncology, Inc. (CSBR)

$7.02

+0.23 (+3.39%)
Rating:
Recommendation:
Buy
Symbol CSBR
Price $7.02
Beta 0.865
Volume Avg. 0.01M
Market Cap 94.927M
Shares () -
52 Week Range 6.11-9.88
1y Target Est -
DCF Unlevered CSBR DCF ->
DCF Levered CSBR LDCF ->
ROE 4.53% Neutral
ROA 1.17% Neutral
Operating Margin -
Debt / Equity 282.83% Strong Buy
P/E 234 Strong Buy
P/B 10.57 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CSBR news


James Heigl
Healthcare
Biotechnology
NASDAQ Capital Market

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.